{
  "id": 8724368,
  "title": "Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching",
  "url": "https://urgent.news/2026/09/20/definiums-lsd-pill-clears-a-second-anxiety-trial-and-the-psychedelics",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-20T16:28:42.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/definium-lsd-pill-clears-second-162842492.html"
  },
  "original_language": "en",
  "account": "Definium Therapeutics, Inc. (DFTX) has secured a second successful Phase 3 trial for its LSD-based medication DT120, aimed at treating generalized anxiety disorder. The 12-week study showed a 9.8-point reduction in anxiety scores compared to a 4.7-point decrease with a placebo, indicating a 5.1-point improvement. This result mirrors that of Definium's previous pivotal trial, Voyage, which demonstrated an 11.6-point improvement with LSD versus 6.2 with placebo. Psychedelic stocks have historically demonstrated a tendency to trade together, with Definium's latest success likely boosting their collective performance. Hedge funds have shown increased interest in DFTX, with the number of funds holding the stock rising from 46 to 72 in the second quarter. This series of positive results for Definium across multiple indications significantly reduces the risk of an FDA approval and moves the company closer to submitting a New Drug Application.",
  "summary": null,
  "key_points": [
    "Definium's LSD-based DT120 clears second Phase 3 trial for anxiety disorder",
    "9.8-point reduction in anxiety scores vs. 4.7-point placebo decrease",
    "Hedge funds increase interest, raising DFTX holders from 46 to 72 in Q2"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}